The knowledge on the rare type of pulmonary hypertension which can not be explained by left heart disease, respiratory disease or congenital heart disease is very limited. Investigators aim to setup a national registration study for the rare type of pulmonary hypertension, to understand the natural history, survival, progression, genetic and environmental contributions to disease.
The main research contents of this registration study includes: 1. Build a baseline database of the rare type of pulmonary hypertension. Collect general information, on-set symptoms and time, laboratory examination, imaging results, right heart catheterization and treatment information. 2. Follow up recruited patients at regular intervals(6m\~1y). Collect information on change in patients condition, laboratory test and treatment. 3. Conduct genetic testing for gene mutation related or hereditary pulmonary hypertension. Link the clinical database to genetic database. 4. Establish bio-bank for serum/plasma, urine, stool, tissues or cells. 5. Establish prognostic study based on the clinical follow-up and genetic database. 6. Draw diagnostic and treatment algorithm for the rare type of pulmonary hypertension. Controls subjects: blood sample and medical data collected once.
Study Type
OBSERVATIONAL
Enrollment
2,000
Laboratory results will be analysed to identify disease related biomarkers.
Gene sequencing results will be analysed to identify disease related mutations.
Chinese Academy of Medical Sciences Fuwai Hospital and Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGSurvival Rate of Participants
Time frame: up to 10 years, at 12 months interval
Lung transplantation
Time frame: up to 10 years, at 12 months interval
Change in New York Heart Association (NYHA) functional class
Time frame: up to 10 years, at 3 months interval
Change in 6 mint walk distance
Time frame: up to 10 years, at 3 months interval
Genetic alteration in participants with rare type of PH
To identify the major genetic alterations in participants with rare type of PH
Time frame: Baseline
Change in NT-proBNP
Time frame: up to 10 years, at 3 months interval
Change in hemodynamics
Time frame: up to 10 years, at 6 months interval
Change in cardiac function
Measured by Cardiac MRI
Time frame: up to 10 years, at 3-6 months interval
Pulmonary endarterectomy (PEA)
e.g. operated versus non-operated
Time frame: up to 10 years, at 6 months interval
Balloon pulmonary angioplasty (BPA)
e.g. BPA versus non-BPA
Time frame: up to 10 years, at 6 months interval
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medical treatment
e.g. mono- versus combination therapy
Time frame: up to 10 years, at 6 months interval